Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.7 |
mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.11 | 0.7 |
mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.028 | 0.7 |